Jennison Associates LLC Acquires New Position in ICU Medical, Inc. (NASDAQ:ICUI)

Jennison Associates LLC bought a new position in shares of ICU Medical, Inc. (NASDAQ:ICUI - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 3,586 shares of the medical instruments supplier's stock, valued at approximately $556,000.

A number of other large investors also recently bought and sold shares of the stock. Allworth Financial LP grew its holdings in ICU Medical by 100.0% in the third quarter. Allworth Financial LP now owns 200 shares of the medical instruments supplier's stock valued at $36,000 after purchasing an additional 100 shares during the period. Equitable Trust Co. raised its position in ICU Medical by 2.2% during the third quarter. Equitable Trust Co. now owns 5,213 shares of the medical instruments supplier's stock worth $950,000 after acquiring an additional 112 shares during the period. Hexagon Capital Partners LLC grew its position in shares of ICU Medical by 162.7% in the third quarter. Hexagon Capital Partners LLC now owns 197 shares of the medical instruments supplier's stock valued at $36,000 after purchasing an additional 122 shares during the period. Connable Office Inc. raised its position in shares of ICU Medical by 6.4% during the 3rd quarter. Connable Office Inc. now owns 2,031 shares of the medical instruments supplier's stock worth $370,000 after purchasing an additional 122 shares during the last quarter. Finally, Gagnon Securities LLC boosted its holdings in ICU Medical by 0.5% in the 4th quarter. Gagnon Securities LLC now owns 28,881 shares of the medical instruments supplier's stock worth $4,481,000 after buying an additional 137 shares during the last quarter. 96.10% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at ICU Medical

In related news, COO Christian B. Voigtlander sold 1,962 shares of the company's stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $169.08, for a total value of $331,734.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Vivek Jain sold 12,000 shares of the business's stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $162.91, for a total value of $1,954,920.00. Following the completion of the sale, the chief executive officer now owns 104,593 shares of the company's stock, valued at approximately $17,039,245.63. This represents a 10.29 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 17,737 shares of company stock worth $2,879,752. 6.70% of the stock is currently owned by insiders.

ICU Medical Trading Down 1.2 %

NASDAQ:ICUI traded down $1.97 on Tuesday, hitting $157.81. The stock had a trading volume of 124,233 shares, compared to its average volume of 200,301. The company has a fifty day moving average price of $160.72 and a two-hundred day moving average price of $164.21. ICU Medical, Inc. has a 1-year low of $93.36 and a 1-year high of $196.26. The company has a quick ratio of 1.03, a current ratio of 2.29 and a debt-to-equity ratio of 0.75. The stock has a market cap of $3.86 billion, a price-to-earnings ratio of -34.53 and a beta of 0.63.

Analysts Set New Price Targets

A number of analysts have recently issued reports on ICUI shares. StockNews.com raised ICU Medical from a "hold" rating to a "buy" rating in a research note on Wednesday, November 20th. Needham & Company LLC reiterated a "hold" rating on shares of ICU Medical in a research report on Wednesday, November 13th. KeyCorp upped their price objective on shares of ICU Medical from $198.00 to $209.00 and gave the company an "overweight" rating in a research note on Wednesday, November 13th. Finally, Jefferies Financial Group raised shares of ICU Medical from a "hold" rating to a "buy" rating and set a $200.00 target price on the stock in a research note on Wednesday, December 11th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, ICU Medical currently has a consensus rating of "Moderate Buy" and a consensus target price of $199.67.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.